AusperBio Therapeutics, Inc. announced that its lead investigational product, AHB-137, achieved a 30% functional cure rate as a 24-week monotherapy in HBeAg-negative chronic hepatitis B patients already on stable nucleos(t)ide analogue therapy. The data, presented at HEP-DART 2025, showed that patients with baseline HBsAg 100–1,000 IU/mL reached this endpoint at Week 72 in the company’s multicenter Phase IIa trial. The result is being interpreted by many as a pivotal moment in the quest for a finite-duration, curative regimen for hepatitis B.

Why this functional cure milestone is attracting industry-wide attention

For decades, chronic hepatitis B therapy has been dominated by nucleos(t)ide analogues that effectively control viral replication but rarely achieve a true cure. Most patients face lifelong therapy to maintain viral suppression and reduce the risk of liver cancer and cirrhosis. Functional cure—defined as undetectable hepatitis B surface antigen and viral DNA off therapy—remains the holy grail in the field. Until now, functional cure rates for any therapy have hovered in the low single digits. The 30% rate reported for AHB-137 monotherapy, in a well-defined HBeAg-negative population, marks a step-change in what is considered achievable for patients and researchers alike.

Industry observers suggest that this result, presented with full end-of-follow-up data, is not just a statistical footnote. It establishes proof of concept that antisense oligonucleotide therapies, if correctly targeted and delivered, can move cure rates from the aspirational to the actionable. The fact that both the 225 mg and 300 mg dose cohorts hit the 30% benchmark adds further weight to the reproducibility of the result.

What sets AHB-137 apart from other investigational HBV cures

Unlike earlier therapies targeting hepatitis B, AHB-137 is an unconjugated antisense oligonucleotide built on AusperBio’s proprietary Med-Oligo ASO platform. Its triple mechanism—targeting HBsAg at the source, suppressing viral DNA, and reactivating the immune system—reflects a multipronged approach that current nucleos(t)ide analogues and many experimental agents do not offer.

Clinicians tracking the field believe that AHB-137’s durable off-treatment responses are especially noteworthy. In this Phase IIa study, all patients who completed therapy and discontinued nucleos(t)ide analogues maintained HBV DNA negativity for at least 24 weeks post-treatment. In addition, nearly nine in ten patients in the key baseline HBsAg group sustained antigen suppression off therapy, suggesting real-world potential to reduce or eliminate the need for ongoing medication.

The design of the AB-10-8002 trial—a randomized, open-label, multicenter Phase II study—was robust for a mid-stage trial, though industry analysts point out that larger, more diverse cohorts will be needed to confirm efficacy across broader populations. Still, for HBeAg-negative patients with moderate baseline antigen levels, AHB-137 appears to offer an efficacy profile that is currently unmatched by other candidates.

What this reveals about the evolving HBV treatment landscape

The findings put antisense oligonucleotide therapies, and AusperBio’s platform in particular, at the center of a new wave of HBV drug development. Unlike gene editing, RNA interference, or immune checkpoint approaches, the antisense strategy seeks to precisely disrupt viral protein production while enabling immune reconstitution. The rapid HBsAg declines observed in the study suggest a different kinetic profile compared to past agents.

Regulatory watchers suggest the trial’s strong safety and tolerability data could help smooth AHB-137’s pathway through later-phase development. The absence of serious drug-related adverse events, and no discontinuations for safety reasons, will be key selling points as AusperBio seeks to scale up its clinical program. However, experts note that the open-label design and the focus on a select patient group mean the findings will need validation in Phase III and real-world settings.

What could change for clinicians and patients if these results hold up

If the 30% functional cure rate is reproduced in larger and more diverse trials, the implications for standard of care in chronic hepatitis B could be dramatic. For clinicians, a finite-duration monotherapy that delivers cure in nearly a third of treated patients would allow for risk-tailored treatment strategies, potentially freeing a significant portion of the hepatitis B population from lifelong antiviral therapy.

Moreover, the data suggest that AHB-137 could serve as a backbone for combination regimens, benefiting patients who do not achieve full cure but reach very low antigen levels. This would enable clinicians to more precisely identify “strong responders” who could be prioritized for add-on therapies, a flexibility that existing regimens lack.

Industry observers note that these findings may also influence payer and reimbursement strategies. A truly curative therapy could command a premium, but will also face the usual hurdles around health economics, access, and pricing in both high- and low-income settings.

What risks, limitations, and unanswered questions remain

While the Phase IIa results are robust and the milestone is clear, several caveats should temper expectations. First, the trial focused on HBeAg-negative patients with moderate baseline HBsAg, leaving open questions about efficacy in those with higher antigen loads or different disease phenotypes. The durability of response beyond the 24-week off-treatment follow-up will be scrutinized, as HBV is well known for late relapses.

Regulators and industry stakeholders will be watching for signals of safety or efficacy drift in broader patient populations, as well as in combination studies. Manufacturing scalability and the global regulatory environment for antisense oligonucleotide therapies are additional risk factors that could affect the speed and reach of AHB-137’s rollout.

While the safety profile is encouraging, the longer-term impact of repeated dosing and the potential for rare adverse events can only be addressed with larger, multi-year datasets. The complex global HBV epidemiology, including high-burden regions such as Asia and Africa, means that access and logistical hurdles will be significant for any new therapy aiming for functional cure.

What the next phase of development and industry scrutiny will focus on

AusperBio has indicated that the 300 mg dose of AHB-137 has been selected for further Phase II and pivotal studies. Clinicians and trialists are keenly interested in the ongoing Phase III trial in China and parallel studies in other geographies. Regulatory clarity—especially around endpoints for functional cure, long-term safety, and real-world deployment—will be closely watched.

Industry analysts expect that the next two to three years will be crucial, both for AHB-137 and for the broader antisense oligonucleotide approach in hepatitis B. The field has seen plenty of “breakthrough” announcements in the past, only to see momentum stall in late-phase trials. The difference this time, some suggest, is the durability and depth of response demonstrated in a real-world dosing scenario.

Regulatory watchers point out that, should AHB-137 achieve approval with a 30% functional cure label, it could spur a wave of new entrants and partnership deals in oligonucleotide-based HBV therapeutics. Intellectual property, manufacturing know-how, and post-marketing surveillance strategies will become battlegrounds as the sector seeks to move beyond chronic suppression to actual cure.

Why this moment matters for industry observers and patients

In a sector long defined by incremental progress, the functional cure rate reported for AHB-137 represents a rare leap forward. Industry observers believe that, if confirmed, this could reset expectations not just for patients and clinicians, but also for investors, regulators, and health systems globally.

Whether AHB-137 ultimately becomes the new standard or simply paves the way for next-generation therapies, the paradigm in hepatitis B drug development has undeniably shifted. For now, AusperBio’s data will remain under the microscope, as clinicians, industry, and patients look for evidence that functional cure is finally moving from promise to practice.

  AHB-137, antisense oligonucleotide, AusperBio, biotech, chronic hepatitis B, functional cure, HBeAg-negative, HBV, Med-Oligo ASO, nucleos(t)ide analogue, oligonucleotide therapy, Phase IIa